GLP-1 and Liver Health: Ozempic for Fatty Liver Disease NAFLD MASH

May 24, 2026

GLP-1 and Liver Health: Ozempic for Fatty Liver Disease (NAFLD/MASH)

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist and founder of Casa de Sante

Key Takeaways

GLP-1 medications are one of the most promising treatments for non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH)
Semaglutide resolved MASH (fatty liver with inflammation) in 59% of patients in the Phase 2 trial — vs 17% with placebo
Resmetirom (Rezdiffra) became the first FDA-approved MASH drug in 2024, but GLP-1 medications address both the liver AND the metabolic syndrome driving it
The mechanism: weight loss reduces liver fat, GLP-1 has direct anti-inflammatory effects on liver cells, and improved insulin sensitivity reduces de novo lipogenesis
NAFLD affects ~30% of the global population and is becoming the leading cause of liver transplantation

Understanding NAFLD and MASH

The Spectrum

NAFLD (simple steatosis): Fat accumulation in the liver (>5% of liver cells contain fat). Often asymptomatic. Reversible with lifestyle changes.
MASH (formerly NASH): Fat + inflammation + liver cell damage. Progresses to fibrosis and cirrhosis if untreated. The dangerous stage.
Fibrosis → Cirrhosis: Scarring replaces healthy liver tissue. Irreversible once advanced. Leads to liver failure and liver cancer risk.

Risk Factors

Obesity, type 2 diabetes, metabolic syndrome, high triglycerides, and insulin resistance. Essentially the same metabolic profile that GLP-1 medications address.

GLP-1 and the Liver

Clinical Evidence

Semaglutide Phase 2 MASH trial: 59% MASH resolution (vs 17% placebo). 43% improvement in fibrosis stage. Dose: 0.4mg daily subcutaneous (higher than standard Ozempic dosing).
Semaglutide Phase 3 (ongoing): Multiple large trials in progress for MASH indication. FDA approval for MASH specifically is anticipated.
Liraglutide (Saxenda): Reduced liver fat by 31% in 6 months. MASH resolution in 39% of patients.
Tirzepatide (Mounjaro/Zepbound): SYNERGY-NASH trial showed even greater liver fat reduction than semaglutide — likely due to dual GIP+GLP-1 mechanism.

How GLP-1 Helps the Liver

Weight loss: 5% weight loss reduces liver fat significantly. 10% weight loss can resolve MASH. GLP-1 medications achieve 15-20% weight loss.
Insulin sensitivity: Improved insulin sensitivity reduces the liver's production of new fat (de novo lipogenesis).
Direct hepatic effects: GLP-1 receptors exist on liver cells. Direct signaling reduces hepatic inflammation and oxidative stress.
Improved lipid profile: GLP-1 reduces triglycerides (the fat that accumulates in the liver) and improves HDL cholesterol.

Supporting Liver Health

Maintain weight loss: The liver benefits are directly proportional to weight loss. Do not regain.
Limit alcohol: Even moderate alcohol adds to liver stress when NAFLD is present.
Mediterranean diet: The dietary pattern with the most evidence for NAFLD reduction. Olive oil, fish, vegetables, nuts, minimal processed food.
Coffee: 2-3 cups daily is hepatoprotective. The polyphenols in coffee reduce liver inflammation and fibrosis risk.
Exercise: Both aerobic and resistance training reduce liver fat independently of weight loss.

🛒 Liver Health Support

Digestive Enzymes — The liver produces bile for fat digestion. When the liver is compromised by NAFLD, bile production may be suboptimal. Supplemental lipase and other enzymes support fat digestion independently of bile, reducing liver workload.
Daily Vitamin — Vitamin E has specific evidence for MASH treatment (800 IU/day reduced liver inflammation in the PIVENS trial). Comprehensive vitamin support including vitamin E, D, and antioxidants supports liver health.
Whey Protein — Adequate protein preserves lean mass during GLP-1 weight loss and provides the amino acids the liver needs for detoxification pathways (especially glutathione synthesis).

Medical Disclaimer: This article is for educational purposes only. NAFLD/MASH diagnosis requires imaging (ultrasound, FibroScan) and potentially liver biopsy. Elevated liver enzymes on routine blood work should be evaluated by a hepatologist or gastroenterologist. Dr. Adegbola is the founder of Casa de Sante.

Back to blog

Keto. Paleo. No Digestive Triggers. Shop Now

No onion, no garlic – no pain. No gluten, no lactose – no bloat. Low FODMAP certified.

Stop worrying about what you can't eat and start enjoying what you can. No bloat, no pain, no problem.

Our gut friendly keto, paleo and low FODMAP certified products are gluten-free, lactose-free, soy free, no additives, preservatives or fillers and all natural for clean nutrition. Try them today and feel the difference!